Status:
UNKNOWN
Honey and Nigella Sativa in COVID-19 Prophylaxis
Lead Sponsor:
Sohaib Ashraf
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis
Eligibility Criteria
Inclusion
- Health care professionals Post-exposure COVID-19
Exclusion
- Multi-organ failure active COVID-19
Key Trial Info
Start Date :
March 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 15 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04767087
Start Date
March 5 2021
End Date
April 15 2022
Last Update
July 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaikh Zayed Post-Graduate Medical Institute
Lahore, MA, Pakistan, 54600